Clinical Trial Update: Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine [Phase 3]

View source ↗

Summary

Phase 3 trial update for ALD403 (eptinezumab) evaluating prevention of chronic migraine; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine Disorders

Drugs mentioned

• ALD403 (eptinezumab) (eptinezumab)

Snippet

Sponsor: Alder Biopharmaceuticals, Inc. | Conditions: Migraine Disorders | Phase 3 | Status: COMPLETED | Results posted: 2020-06-09